BTIG analyst Mark Massaro upgraded Neogenomics (NASDAQ: NEO) from Neutral to Buy with a price target of $28.00.The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments Hot Upgrades Upgrades